Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks
Article first published online: 29 SEP 2005
Volume 96, Issue 9, pages 1319–1322, December 2005
How to Cite
Donohue, J. F., Hayne, D., Karnik, U., Thomas, D. R. and Foster, M. C. (2005), Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. BJU International, 96: 1319–1322. doi: 10.1111/j.1464-410X.2005.05849.x
- Issue published online: 15 NOV 2005
- Article first published online: 29 SEP 2005
- Accepted for publication 25 July 2005
- microvessel density;
To measure expression of vascular endothelial growth factor (VEGF) and microvessel density (MVD) in the prostates of men after transurethral resection of the prostate (TURP) following 2 weeks of treatment with finasteride.
PATIENTS AND METHODS
Sixty-four men scheduled to undergo TURP were randomized to receive 5 mg of finasteride or placebo daily for 2 weeks before surgery. Sections of prostatic urothelium were stained for VEGF expression and for CD31 to assess MVD. Ten consecutive, non-overlapping high-power fields were analysed in a blinded fashion.
In all, 31 men received finasteride and 33 placebo; the groups were similar in patient age, resected prostate weight, preoperative catheterization, prostate-specific antigen level, aspirin use, spinal anaesthesia and postoperative diagnosis of prostate cancer. The mean (95% confidence interval) MVD was significantly lower in the finasteride group (60, 55–65) than in the placebo group (71, 64–78; P < 0.01). Similarly, the mean expression of VEGF was significantly lower in the finasteride group (47, 43–52 vs 61, 54–67; P < 0.001)
Finasteride inhibits angiogenic growth factors leading to reduced vascularity, and this is the basis of its action in reducing haematuria of prostatic origin. The present study shows that finasteride influences the prostatic microvasculature after only 2 weeks exposure.